To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Cellular and Molecular Neuroscience,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s10571-019-00730-3.pdf
Reference91 articles.
1. Amelot A, Cremoux PD, Quillien V et al (2015) IDH-mutation is a weak predictor of long-term survival in glioblastoma patients. PLoS ONE 10:e0130596. https://doi.org/10.1371/journal.pone.0130596
2. Annovazzi L, Mellai M, Bovio E et al (2018) Microglia immunophenotyping in gliomas. Oncol Lett 15:998–1006. https://doi.org/10.3892/ol.2017.7386
3. Berghoff AS, Kiesel B, Widhalm G et al (2017) Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-oncology 19:1460–1468. https://doi.org/10.1093/neuonc/nox054
4. Bralten LBC, French PJ (2011) Genetic Alterations in Glioma. Cancers (Basel) 3:1129–1140. https://doi.org/10.3390/cancers3011129
5. Bunse L, Pusch S, Bunse T et al (2018) Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med 24:1192. https://doi.org/10.1038/s41591-018-0095-6
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study;European Journal of Medicinal Chemistry;2024-09
2. Control of CDH1 and IDH1mut glioblastoma cell cycle by D-2- hydroxyglutarate;2024-04-19
3. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation;Cancer Letters;2024-04
4. Role of N6-methyladenosine methylation in glioma: recent insights and future directions;Cellular & Molecular Biology Letters;2023-12-11
5. Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma;European Journal of Medicinal Chemistry;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3